Infectious Disease / Microbiology Updates
6.58K subscribers
31 photos
3 videos
23 files
3.71K links
All the atest articles, research and news from worlds leading Infectious Disease Journals.

Discussion group
https://t.me/Professional_Medical_Discussion
Download Telegram
[Corrections] Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00120-9/fulltext?rss=yes

Heysell SK, Mpagama SG, Nuwagira E, et al. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. Lancet Infect Dis 2026; published online Jan 28. https://doi/org/10.1016/S1473-3099(25)00747-9—In this Article, the p value in the Findings in the Summary for patients with microbiologically confirmed tuberculosis in the diagnosis-dependent high-dose group compared with the diagnosis-dependent conventional-dose group should have been 0·079.
[Profile] Katharina Kranzer—led by curiosity, committed to capacity
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00127-1/fulltext?rss=yes

Katharina Kranzer has always wanted to understand how things work. As a child moving between the USA, Austria, and Germany due to her father's work as a physicist, she developed early a habit of examining systems from the outside. She briefly considered studying history and politics, but her mother helped convince her medicine offered something more tangible: a way to interrogate the world and change it. At the Technical University of Munich, Germany, where she chose to study in part to be close to the mountains she loved, it was not the routine of clinical training that captivated her.
[Editorial] GoGoVax dispels hopes for gonorrhoea vaccination
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00126-X/fulltext?rss=yes

In 2020, WHO estimated that there were 82·4 million new infections with Neisseria gonorrhoeae among adults aged 15–49 years and up to 2022, the incidence of gonorrhoea had been on the rise globally for a decade. While in the last three years a decrease in the number of cases has been observed in several countries, including the USA and the UK, with antimicrobial resistance constituting a major barrier to treatment and no gonorrhoea vaccine available, protecting populations at risk from the disease remains a challenge.
👍1
[Corrections] Correction to Lancet Infect Dis 2026; 26: 343–61
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00124-6/fulltext?rss=yes

GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis 2026; 26: 343–61—In the Declaration of interests section of this Article, the statement has been corrected for Bogdan Oancea. This correction has been made to the online version as of March 25, 2026, and the printed version is correct.
1
[Newsdesk] Research in brief
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00129-5/fulltext?rss=yes

A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.
3👍1
[Comment] Structural stigma: an urgent intervention priority in Africa
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00359-5/fulltext?rss=yes

Improved access to antiretroviral therapy (ART) for people with HIV has greatly affected the trajectory of the global HIV pandemic, enabling people with HIV to lead long, healthy lives and curtailing the number of people who newly acquire HIV. Between 2000 and 2024, the number of people with HIV accessing ART globally increased from 370 000 to 31·6 million.1 Over the same period, the percentage of people with HIV accessing ART increased from 0% to 83% in Africa,2 a region that accounts for nearly two-thirds of the 40·8 million people with HIV worldwide.